About Kamari Pharma

Kamari Pharma develops TRPV3 inhibitors that repair skin damage associated with rare dermatological diseases and chronic itch. Their technology targets the TRPV3 channel, a key regulator of skin homeostasis, to address significant gaps in treatment options for patients.

```xml <problem> Many rare dermatological diseases and conditions causing chronic itch lack effective treatment options, leaving patients with limited relief from skin damage and discomfort. Current therapies often fail to address the underlying causes of these conditions, resulting in persistent symptoms and reduced quality of life. </problem> <solution> Kamari Pharma is developing TRPV3 inhibitors designed to repair skin damage and alleviate chronic itch associated with rare dermatological diseases. Their technology targets the TRPV3 channel, a key regulator of skin homeostasis, to restore balance and function within the skin. By modulating TRPV3 activity, Kamari Pharma aims to provide innovative treatments that address the root causes of these conditions, offering patients improved symptom management and enhanced skin health. The inhibitors represent a novel approach to patient care, offering a potential breakthrough in the treatment of unmet needs in rare skin diseases. </solution> <features> - TRPV3 inhibitors designed to modulate the activity of the TRPV3 channel. - Targeted approach to restore skin homeostasis and repair skin damage. - Potential to alleviate chronic itch associated with various dermatological conditions. - Focus on addressing unmet needs in the treatment of rare skin diseases. </features> <target_audience> The primary target audience includes patients suffering from rare dermatological diseases and chronic itch, as well as dermatologists and other healthcare professionals seeking innovative treatment options for these conditions. </target_audience> ```

What does Kamari Pharma do?

Where is Kamari Pharma located?

Kamari Pharma is based in Ness Ziona, Israel.

When was Kamari Pharma founded?

Kamari Pharma was founded in 2018.

How much funding has Kamari Pharma raised?

Kamari Pharma has raised 16000000.

Location

Ness Ziona, Israel

Founded

2018

Funding

16000000

Employees

8 employees

Major Investors

GIBF

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Kamari Pharma

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

kamaripharma.com 100+

Crunchbase

Founded 2018 – Ness Ziona, Israel

Funding

Estimated Funding

$10M+

Major Investors

GIBF

Team (5+)

No team information available.

Company Description

Problem

Many rare dermatological diseases and conditions causing chronic itch lack effective treatment options, leaving patients with limited relief from skin damage and discomfort. Current therapies often fail to address the underlying causes of these conditions, resulting in persistent symptoms and reduced quality of life.

Solution

Kamari Pharma is developing TRPV3 inhibitors designed to repair skin damage and alleviate chronic itch associated with rare dermatological diseases. Their technology targets the TRPV3 channel, a key regulator of skin homeostasis, to restore balance and function within the skin. By modulating TRPV3 activity, Kamari Pharma aims to provide innovative treatments that address the root causes of these conditions, offering patients improved symptom management and enhanced skin health. The inhibitors represent a novel approach to patient care, offering a potential breakthrough in the treatment of unmet needs in rare skin diseases.

Features

TRPV3 inhibitors designed to modulate the activity of the TRPV3 channel.

Targeted approach to restore skin homeostasis and repair skin damage.

Potential to alleviate chronic itch associated with various dermatological conditions.

Focus on addressing unmet needs in the treatment of rare skin diseases.

Target Audience

The primary target audience includes patients suffering from rare dermatological diseases and chronic itch, as well as dermatologists and other healthcare professionals seeking innovative treatment options for these conditions.